Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR 3.888
-0.102 (-2.56%)
At close: Jan 30, 2026
Valneva SE Market Cap
Valneva SE has a market cap or net worth of €674.24 million as of January 30, 2026. Its market cap has increased by 92.03% in one year.
Market Cap
674.24M
Enterprise Value
726.62M
Revenue
179.91M
Ranking
n/a
PE Ratio
n/a
Stock Price
€3.89
Market Cap Chart
Since June 29, 2007, Valneva SE's market cap has increased from 99.08M to 674.24M, an increase of 580.51%. That is a compound annual growth rate of 10.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 674.24M | 4.97% |
| Dec 31, 2025 | 642.32M | 82.94% |
| Dec 31, 2024 | 351.10M | -46.40% |
| Dec 29, 2023 | 655.08M | -23.93% |
| Dec 30, 2022 | 861.12M | -66.55% |
| Dec 31, 2021 | 2.57B | 265.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| DBV Technologies | 1.12B |
| Inventiva | 955.16M |
| Nanobiotix | 844.85M |
| MedinCell | 746.80M |
| Genfit | 278.85M |
| Transgene | 248.09M |
| Cellectis | 235.06M |
| Innate Pharma | 145.05M |